Comment combler l’écart entre les essais cliniques et la pratique médicale courante dans les rhumatismes inflammatoires chroniques?
-
Published:2022-06
Issue:4
Volume:89
Page:329-331
-
ISSN:1169-8330
-
Container-title:Revue du Rhumatisme
-
language:fr
-
Short-container-title:Revue du Rhumatisme
Reference25 articles.
1. Usefulness of realword-patient cohort follow-up using questionnaires to assess the effect of treatments on the general population;Berthelot;Joint Bone Spine,2021
2. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1);Westhovens;Ann Rheum Dis,2017
3. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis;Taylor;N Engl J Med,2017
4. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study;Dougados;Rheumatology (Oxford),2013
5. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. EXCEED Study Group;McInnes;Lancet,2020